Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endo...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11 December 2018
|
| In: |
BMC ophthalmology
Year: 2018, Volume: 18 |
| ISSN: | 1471-2415 |
| DOI: | 10.1186/s12886-018-0978-9 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12886-018-0978-9 Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12886-018-0978-9 
|
| Author Notes: | Patrick R. Merz, Nina Röckel, Seda Ballikaya, Gerd U. Auffarth and Ingo Schmack |
| Summary: | Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endothelial growth factor (VEGF) antibodies. The aim of the study was to investigate potential cytotoxic effects of two anti-VEGF agents, ranibizumab (Lucentis®) and bevacizumab (Avastin®) on the human corneal endothelium. |
|---|---|
| Item Description: | Gesehen am 21.12.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1471-2415 |
| DOI: | 10.1186/s12886-018-0978-9 |